ACH-3102 is an investigational new drug in development for the treatment of the viral infection known as hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.
- ACH-3102 resources. Achillion pharmaceuticals. Winter 2011. Accessed May 2012.
- Achillion gets FDA incentives for hepatitis C drug. Associated Press. 15 May 2012.
- Levin, Jules. Preclinical characteristics of ACH-3102. Conference report. European Association for the Study of the Liver, 47th Annual Meeting. April 18th - 22nd 2012. Barcelona, Spain
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|